CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER
NDA 21-492

Microbiology Review(s)

Product Quality Microbiology Review
Review for HFD-150

22 JULY 2002

NDA: 21-492

Drug Product Name
Proprietary: Eloxatine
Non-proprietary: oxaliplatin for injection
Drug Product Classification: P

Review Number: 1

Subject of this Review
Submission Date: 15 April 2002
Receipt Date: 15 April 2002
Consult Date: 20 May 2002
Date Assigned for Review: 6 June 2002

Submission History (for amendments only)
Date(s) of Previous Submission(s): N/A
Date(s) of Previous Micro Review(s): N/A

Applicant/Sponsor
Name: Sanofi-Synthelabo Inc.
Address: 9 Great Valley Parkway; P.O. Box 3026; Malvern, PA 19355
Representative: Mark Moyer, Director, Drug Regulatory Affairs
Telephone: 610-889-6417

Name of Reviewer: Bryan S. Riley, Ph.D.

Conclusion: Recommended for Approval

Product Quality Microbiology Data Sheet

A. 1. **TYPE OF SUPPLEMENT:** N/A

2. **SUPPLEMENT PROVIDES FOR:** N/A

3. **MANUFACTURING SITE:** Ben Venue Laboratories
Bedford, OH 44146

4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:** Lyophilized powder in a glass vial for I.V. administration, 50 and 100 mg/vial

5. **METHOD(S) OF STERILIZATION:** —

6. **PHARMACOLOGICAL CATEGORY:** treatment of colorectal cancer

B. **SUPPORTING/RELATED DOCUMENTS:** Microbiology reviews of NDAs 21-063 (dated 29 November 1999), 16-093/S-042, 20-038/S-024&025 and 50-718/S-015.

C. **REMARKS:** This NDA was originally submitted, and later withdrawn, as NDA 21-063 (Eloxatin for injection). The original product quality microbiology review of NDA 21-063 was completed, and 2 microbiology deficiencies were identified in the submission. The current submission contains changes made in response to the microbiology deficiencies in the original NDA (21-063). Additionally, the filling line has been refurbished since the review of the original NDA. The refurbished filling line has been reviewed, and recommended for approval, for other NDA supplements (see section B. above) for sterile products.

filename: 21492.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability – This submission is recommended for approval on the basis of product quality microbiology.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable – N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – The drug product is ——— and lyophilized.

B. Brief Description of Microbiology Deficiencies – N/A

C. Assessment of Risk Due to Microbiology Deficiencies – The ——— process was previously reviewed in NDA 21-063 and was considered approvable with 2 microbiology deficiencies. The current submission adequately addressed the deficiencies and the drug product therefore presents a low risk from the standpoint of product quality microbiology.

III. Administrative

/S/

A. Reviewer's Signature _____

B. Endorsement Block
Bryan S. Riley, Ph.D. (Microbiology Reviewer)
Peter H. Cooney, Ph.D. (Microbiology Supervisor)

C. CC Block
N/A

Redacted 2

pages of trade

secret and/or

confidential

commercial

information

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Bryan Riley
7/22/02 02:15:45 PM
MICROBIOLOGIST

Peter Cooney
7/22/02 02:27:06 PM
MICROBIOLOGIST

Redacted 3

pages of trade

secret and/or

confidential

commercial

information

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Haripada Sarker
7/19/02 05:42:54 PM
CHEMIST

Richard Lostritto
7/22/02 05:23:42 PM
CHEMIST

Christy Wilson
7/23/02 08:46:35 AM
CSO

MEMORANDUM

Date: August 8, 2002

From: John K. Leighton, Ph.D., DABT
Associate Director for Pharmacology/Toxicology, ODE I (acting for Dr. El Hage)

To: Dr. Robert Temple
Director, ODE I

Re: NDA 21-492
Eloxatin (oxaliplatin)

The NDA pharmacology/toxicology memorandum states that the label will be reviewed separately. The Division has conducted a comprehensive review of the pharmacology and toxicology of oxaliplatin. Pharmacology/toxicology staff participated in the labeling review meetings and comments were incorporated into the draft label revisions during the course of those meetings. Therefore, no separate label review will be provided by Division pharmacology/toxicology staff.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

John Leighton
8/8/02 11:38:29 AM
PHARMACOLOGIST